OLATHE, Kansas — Ronawk, innovators in stem cell expansion technologies, has launched a trial program to provide its patented tissue-blocks (T-Blocks) to commercial cell producers and regenerative medicine partners. Their T-Blocks are a 3D matrix consumable product that enable the stem cell industry by providing means to increase stem cell production by 3,600 times vs. traditional expansion methods. [Read more…]
Stem Cell Treatment Now Available in the UK, as LifePlus Stem Cells Launches in London
July 21, 2020 — LifePlus Stem Cells is the first Stem Cell service in the UK to provide doctors and prescribers with quantifiable, quality assured autologous and allogeneic stem cells, with appropriate HTA and MHRA licenses.
Patients in the UK can now benefit from Stem Cell treatments prescribed as a medicine, which can be used for a wide range of conditions. [Read more…]
Vita Therapeutics Receives Orphan Drug Designation from FDA for Allogenic iPSC-based Therapy
BALTIMORE, July 23, 2020 — Vita Therapeutics, Inc. has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for VTA-110, a novel regenerative therapy for the treatment of Duchenne’s Muscular Dystrophy (DMD).
VTA-110, is a potential first-in-class allogenic iPSC-based therapy that has shown the ability to repair and regenerate healthy muscle in preclinical studies and has the potential to benefit patients with DMD. [Read more…]
Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update
MELBOURNE, Australia, May 08, 2020 — Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received ethics committee approval to commence a clinical trial to investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19. In addition, the Company also provides updated guidance on its wider clinical development pipeline. [Read more…]
Critically Ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R)
GOLDEN, CO July 14, 2020 — Vitro Diagnostics, Inc. (OTC PINK:VODG), dba Vitro Biopharma, jointly with GIOSTAR – a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science – announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®. [Read more…]
